High-Dose Dexamethasone Versus Tocilizumab in Moderate to Severe COVID-19 Pneumonia: A Randomized Controlled Trial

Background and objectives Recent randomized controlled trials (RCTs) have indicated potential therapeutic benefits with high-dose dexamethasone (HDD) or tocilizumab (TCZ) plus standard care in moderate to severe coronavirus disease 2019 (COVID-19) with acute respiratory distress syndrome (ARDS). No...

Descripción completa

Detalles Bibliográficos
Autores principales: Naik, Naveen B, Puri, Goverdhan D, Kajal, Kamal, Mahajan, Varun, Bhalla, Ashish, Kataria, Sandeep, Singla, Karan, Panigrahi, Pritam, Singh, Ajay, Lazar, Michelle, Chander, Anjuman, Ganesh, Venkata, Hazarika, Amarjyoti, Suri, Vikas, Goyal, Manoj K, Pandey, Vijayant Kumar, Kaloria, Narender, Samra, Tanvir, Saini, Kulbhushan, Soni, Shiv L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Emergency Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752381/
https://www.ncbi.nlm.nih.gov/pubmed/35036193
http://dx.doi.org/10.7759/cureus.20353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752381/
https://www.ncbi.nlm.nih.gov/pubmed/35036193
http://dx.doi.org/10.7759/cureus.20353

Ejemplares similares